634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

• DOI: 10.1136/jitc-2023-sitc2023.0634
• Publication Date: 2023-10-31T14:03:25Z
• Authors: Salman R Punekar; Theodore Welling; J Randolph Hecht; Julian Molina; Caleb Smith; Edward Garon; M Pia Morelli; Marwan Fakih; Kedar Kirtane; Patrick M Grierson; Sandip P Patel; Yi Lin; Scott Kopetz; Frederick L Locke; Jeffrey Ward; Ariane Lozac’hmeur; Matthew Frigault; Sarah Nikiforow; Wen-Kai Weng; Jennifer Specht; Tomislav Dragovich; Judy Vong; Armen Mardiros; Kirstin Liechty; William Y Go; John Welch; Eric W Ng; Marcela Maus; David Maloney; Diane M Simeone
• Keywords: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282